HOME >> BIOLOGY >> NEWS
Actonel significantly reduced moderate and severe vertebral fractures

San Antonio, TX (September 20, 2002) A new analysis of scientific data presented at today's meeting of the American Society for Bone and Mineral Research (ASBMR) showed that a 5 mg dose of Actonel (risedronate sodium tablets) daily significantly reduced moderate and severe vertebral fracture risk by 70 percent within one year in postmenopausal women with osteoporosis. Furthermore, the significant effect on vertebral fracture risk was sustained over three years.

This analysis combined data from two large Actonel clinical trials, VERT-NA and VERT-MN, which included postmenopausal women with either one prevalent vertebral fracture and low bone mineral density (BMD), or with at least two prevalent vertebral fractures. The objective of this analysis was to compare the incidence of moderate or severe vertebral fracture at one year in women who received Actonel or placebo. Fracture severity was determined using the fracture severity scoring system developed by Harry Genant, M.D., Professor of Radiology, Medicine, Epidemiology and Orthopaedic Surgery at the University of California, San Francisco, an investigator and pioneer of the assessment method used in the analysis.

Recent studies show severity of prevalent vertebral fractures is a predictor of future vertebral and non-vertebral fracture risk; patients with more severe baseline vertebral fractures are more likely to experience subsequent vertebral and non-vertebral fractures. Therefore, reducing the incidence of moderate or severe vertebral fractures may help decrease the risk of future fractures.

"The ultimate goal of osteoporosis treatment is to prevent fractures," said Dr. Genant, "These new findings, combined with previous Actonel clinical data showing reductions in both risk of first vertebral fracture and multiple vertebral fractures, suggest that Actonel reduces fracture risk across a range of osteoporotic severity."

According to
'"/>


20-Sep-2002


Page: 1 2 3 4

Related biology news :

1. Rare mutations can significantly increase risk factor for heart disease
2. Cancer health risk significantly underestimated by EPAs ambient model estimates
3. Double mastectomies significantly lower risk of breast cancer in women who are genetically at risk
4. HAART therapy significantly prolongs survival in AIDS patients with central nervous system lymphoma
5. ENBREL rapidly, significantly improved back pain, mobility, function in ankylosing spondylitis
6. Once weekly ENBREL significantly reduced rheumatoid arthritis pain, inflammation & improved function
7. Cognitive abilities increase significantly with time in most prematurely born children
8. Combining key ingredients of vegetarian diet cuts cholesterol significantly, says study
9. Pollen productionand allergiesmay rise significantly over next 50 years
10. Brain size in premature infants significantly smaller than full-term babies
11. Multicenter study shows Benecol spread significantly reduces cholesterol levels in patients taking statin drugs

Post Your Comments:
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... 2015-2019"  report to their offering. One ... technology. With continuous advances in technology, it is important ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
(Date:1/22/2015)... Jersey , 22 de enero de 2015  El Dr. ... hoy su llamada a nominaciones para 2015. Este prestigioso ... hecho, o tiene el potencial para hacer, contribuciones destacadas ... se aceptarán hasta el 15 de marzo de 2015 ...
(Date:1/22/2015)... 2015  Varian Medical Systems (NYSE: VAR ), world ... its commitment to sustainability with inclusion on a prestigious list ... ranked healthcare equipment company among the Corporate Knights Global 100 ... Forum at Davos, Switzerland . ...
(Date:1/22/2015)... 2015  Derma Sciences, Inc. (Nasdaq: DSCI ... wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic ... to the Premier, Inc. Regenerative Skin Grafting contract ... AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue to ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval ... for the use of Medtronic,s SynchroMed ® II ... for use with United Therapeutics, Remodulin ® (treprostinil) ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
Cached News: